"Combo" Multi-Target Pharmacological Therapy and New Formulations to Reduce Inflammation and Improve Endogenous...

Area of Science:

• Neuroscience
• Biomedical Engineering
• Regenerative Medicine

Background:

• Spinal cord injury (SCI) causes irreversible sensory and motor deficits.
• Current treatments for SCI are limited, with no cure available.
• Effective strategies for myelin repair and limiting secondary degeneration are crucial.

Purpose of the Study:

• To develop and evaluate a novel nanomedicine-based multitherapy for spinal cord injury.
• To investigate the efficacy of triiodothyronine-loaded nanomedicines combined with ibuprofen and nerve growth factor.
• To assess the potential of controlled local drug delivery for improving SCI outcomes.

Main Methods:

• Development of poly-L-lactic-co-glycolic acid (PLGA) nanomedicines loaded with triiodothyronine (T3).
• In vitro assessment of T3-nanomedicine efficacy on oligodendrocyte precursor cell differentiation.
• In vivo studies in a rat contusion SCI model to evaluate nanomedicine biodistribution and combination therapy effects (short- and long-term).

Main Results:

• T3-nanomedicines demonstrated efficacy in differentiating oligodendrocyte precursor cells in vitro.
• In vivo, the combination therapy showed short-term anti-inflammatory effects (reduced M1 microglia, glutamate) and long-term improvements in myelination (increased NG2-IR, MBP content) and reduced demyelination.
• Nanomedicines facilitated controlled local drug delivery.

Conclusions:

• Nanomedicine-based delivery systems are effective for controlled drug release in SCI.
• The developed multitherapy, combining T3-loaded nanomedicines with systemic ibuprofen and mNGF, shows promise for improving myelin repair and functional outcomes after SCI.
• This approach represents a potential breakthrough in managing the complex cascade of events following spinal cord injury.